RiverVest, Sante, Third Point Ventures lead funding in Lyric Pharmaceuticals
RiverVest Venture Partners, Sante Ventures and Third Point Ventures have co-led an initial close of a $20.4 million Series A funding round in Lyric Pharmaceuticals Inc, a clinical stage company developing therapeutics for gastrointestinal disease. Lyric closed an $825,000 seed funding round led by RiverVest last year.
27 February 2015•1 min read
